-
Product Insights
NewNet Present Value Model: Savara Inc’s Molgradex
Empower your strategies with our Net Present Value Model: Savara Inc's Molgradex report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – Savara Inc
Savara Inc (Savara), formerly Mast Therapeutics Inc, is a clinical-stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of PAP; and AeroVanc, an inhaled formulation of vancomycin for the treatment of CF. The company has subsidiaries in the US, and Denmark. Savara is headquartered in Austin, Texas,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Molgramostim in Mycobacterium Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Molgramostim in Mycobacterium Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Molgramostim in Mycobacterium Infections Drug Details: Molgramostim (Molgradex) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Molgramostim in Lung Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Molgramostim in Lung Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Molgramostim in Lung Disease Drug Details: Molgramostim (Molgradex) is under development...
-
Product Insights
Bronchiectasis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Bronchiectasis Clinical Trial Report Overview A total of 394 Bronchiectasis clinical trials were conducted as of March 2024. The Bronchiectasis clinical trial report provides a comprehensive understanding of the Bronchiectasis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       ...
-
Product Insights
NewIschemic Stroke – Drugs In Development, 2024
Empower your strategies with our Ischemic Stroke – Drugs In Development, 2024 report and make more profitable business decisions. Ischemic stroke occurs when there is a disruption of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This can happen when a blood vessel that supplies blood to the brain becomes blocked or narrowed, often due to the formation of a blood clot or plaque buildup within the vessel. The blockage can occur within...
-
Product Insights
Inhalers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Inhalers Pipeline Market Report Overview Inhalers deliver medication to the lungs. The inhalers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segment ·       Dry Powder Inhaler Devices Key Territories ·       The US ·       Europe ·       Australia...
-
Product Insights
Net Present Value Model: Editas Medicine Inc’s EDIT-301
Empower your strategies with our Net Present Value Model: Editas Medicine Inc's EDIT-301 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Profile
Savara Inc – Company Profile
Savara Inc (Savara), formerly Mast Therapeutics Inc, is a clinical-stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of PAP. The company has subsidiaries in the US, and Denmark. Savara is headquartered in Austin, Texas, the US.
Add to Basket -
Product Insights
Net Present Value Model: Molgradex
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Molgradex Drug Details Molgramostim (Molgradex) is...